{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T19:02:41Z","timestamp":1770145361802,"version":"3.49.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"DOI":"10.2146\/ajhp110572","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T23:11:57Z","timestamp":1356045117000},"page":"23-33","source":"Crossref","is-referenced-by-count":20,"title":["Oritavancin: An investigational lipoglycopeptide antibiotic"],"prefix":"10.1093","volume":"70","author":[{"given":"Lamis R.","family":"Karaoui","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"EL-Lababidi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Services, Department of Pharmacy, Florida Hospital Orlando, Orlando, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041607531546400_b1-0700023","article-title":"Targanta Therapeutics: hitting a moving target","author":"Daemmrich","year":"2009"},{"key":"2019041607531546400_b2-0700023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/13543784.15.4.417","article-title":"Oritavancin\u2014an investigational glycopeptide antibiotic","volume":"15","author":"Ward","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"2019041607531546400_b3-0700023","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2010.06.048","article-title":"Oritavancin: a novel lipoglycopeptide active against gram-positive pathogens including multiresistant strains","volume":"36","author":"Bouza","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2019041607531546400_b4-0700023","first-page":"25","article-title":"Emerging treatment options for complicated skin and skin structure infections: oritavancin","volume":"2","author":"Townsend","year":"2010","journal-title":"Clin Med Insights Ther"},{"key":"2019041607531546400_b5-0700023","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"2019041607531546400_b6-0700023","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Allen","year":"2003","journal-title":"FEMS Microbiol Rev"},{"key":"2019041607531546400_b7-0700023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1592\/phco.30.1.80","article-title":"A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin","volume":"30","author":"Guskey","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2019041607531546400_b8-0700023","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1592\/phco.24.1.58.34808","article-title":"Oritavancin and tigecycline: investigational antimicrobials for multi-drug-resistant bacteria","volume":"24","author":"Guay","year":"2004","journal-title":"Pharmacotherapy"},{"key":"2019041607531546400_b9-0700023","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jmb.2009.06.064","article-title":"Vancomycin and oritavancin have different modes of action in Enterococcus faecium","volume":"392","author":"Patti","year":"2009","journal-title":"J Mol Biol"},{"key":"2019041607531546400_b10-0700023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"J Mol Biol"},{"key":"2019041607531546400_b11-0700023","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1128\/AAC.00952-09","article-title":"Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates","volume":"53","author":"Arhin","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b12-0700023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2003.09.004","article-title":"Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates","volume":"48","author":"Streit","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019041607531546400_b13-0700023","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","article-title":"In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates","volume":"54","author":"Mendes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b14-0700023","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.diagmicrobio.2010.03.009","article-title":"Worldwide summary of telavancin spectrum and potency against gram-positive pathogens: 2007 to 2008 surveillance results","volume":"67","author":"Putnam","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019041607531546400_b15-0700023","article-title":"Activity of oritavancin against S. aureus, S. epidermidis, Enterococcus spp. and S. pneumoniae, isolated from Canadian hospitals: results of the CANWARD 2007","volume-title":"Paper presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Annual Meeting","author":"Vashisht"},{"key":"2019041607531546400_b16-0700023","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","article-title":"Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing","volume":"52","author":"Arhin","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b17-0700023","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jac\/dkp286","article-title":"Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin","volume":"64","author":"Arhin","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b18-0700023","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/jac\/dkn276","article-title":"In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin","volume":"62","author":"O\u2019Connor","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b19-0700023","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anaerobe.2004.10.005","article-title":"In vitro activity of oritavancin (LY333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic gram-positive cocci","volume":"11","author":"Citron","year":"2005","journal-title":"Anaerobe"},{"key":"2019041607531546400_b20-0700023","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/AAC.00360-08","article-title":"Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax","volume":"52","author":"Heine","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b21-0700023","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b22-0700023","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1128\/AAC.47.7.2283-2292.2003","article-title":"Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages","volume":"47","author":"Seral","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b23-0700023","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/47.5.705","article-title":"Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model","volume":"47","author":"Rupp","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b24-0700023","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.42.4.981","article-title":"Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis","volume":"42","author":"Kaatz","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b25-0700023","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1128\/AAC.45.7.2169-2172.2001","article-title":"Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin","volume":"45","author":"Gerber","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b26-0700023","article-title":"Selection studies for oritavancin-resistant Staphylococcus aureus and enterococci","volume-title":"Abstract presented at 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Sahm"},{"key":"2019041607531546400_b27-0700023","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/48.2.283","article-title":"In vitro activity of LY333328 (oritavancin) against gram-positive aerobic cocci and synergy with ciprofoxacin against enterococci","volume":"48","author":"Noviello","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b28-0700023","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.42.10.2564","article-title":"Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium","volume":"42","author":"Baltch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b29-0700023","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1128\/AAC.43.3.592","article-title":"Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model","volume":"43","author":"Zelenitsky","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b30-0700023","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jac\/dkn358","article-title":"Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model","volume":"62","author":"Baines","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b31-0700023","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1128\/AAC.00361-08","article-title":"Assessment by time-kill methodology of the synergistic effect of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus","volume":"52","author":"Belley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b32-0700023","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1128\/AAC.01146-08","article-title":"Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by Staphylococcus aureus small-colony variant strains isolated from a cystic fibrosis patient: study of antibiotic combinations","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b33-0700023","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00231-09","article-title":"Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia","volume":"53","author":"Rubino","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b34-0700023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects","volume":"50","author":"Bhavnani","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019041607531546400_b35-0700023","article-title":"Protein binding of 14C-oritavancin","volume-title":"Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Rowe"},{"key":"2019041607531546400_b36-0700023","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/AAC.00197-09","article-title":"Impact of human serum albumin on oritavancin in vitro activity against enterococci","volume":"53","author":"McKay","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b37-0700023","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.diagmicrobio.2009.05.022","article-title":"Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus","volume":"65","author":"Arhin","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019041607531546400_b38-0700023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","article-title":"Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose","volume":"49","author":"Fetterly","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b39-0700023","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","article-title":"Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia","volume":"50","author":"Bhavnani","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b40-0700023","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/AAC.47.5.1700-1706.2003","article-title":"Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection","volume":"47","author":"Boylan","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b41-0700023","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b42-0700023","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1128\/AAC.45.3.706-709.2001","article-title":"Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model","volume":"45","author":"Coyle","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b43-0700023","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ijantimicag.2009.08.012","article-title":"Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes","volume":"34","author":"Arhin","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2019041607531546400_b44-0700023","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1469-0691.2008.02035.x","article-title":"Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis","volume":"14","author":"Lemaire","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2019041607531546400_b45-0700023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/dkf058","article-title":"Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium","volume":"50","author":"Mercier","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2019041607531546400_b46-0700023","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1128\/AAC.42.9.2427","article-title":"Infuence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus","volume":"42","author":"Zhanel","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b47-0700023","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1128\/AAC.41.6.1307","article-title":"Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium","volume":"41","author":"Mercier","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b48-0700023","article-title":"Microbiological outcomes and pharmacokinetics of oritavancin in patients with gram-positive bacteremia","volume-title":"Paper presented at 12th European Congress of Clinical Microbiology and Infectious Diseases","author":"De la Pena"},{"key":"2019041607531546400_b49-0700023","article-title":"Phase 2 trial comparing four regimens of oritavancin in the treatment of patients with Staphylococcus aureus bacteremia","volume-title":"Paper presented at 14th European Congress of Clinical Microbiology and Infectious Diseases","author":"Loutit"},{"key":"2019041607531546400_b50-0700023","article-title":"Efficacy of oritavancin at single or infrequent doses for the treatment of complicated skin and skin-structure infections","volume-title":"Paper presented at 19th European Congress of Clinical Microbiology and Infectious Diseases","author":"Dunbar"},{"key":"2019041607531546400_b51-0700023","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1128\/AAC.00029-11","article-title":"Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial","volume":"55","author":"Dunbar","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b52-0700023","article-title":"Equivalence of shorter course therapy with oritavancin compared to vancomycin\/cephalexin in complicated skin\/skin structure infections","volume-title":"Paper presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Wasilewski"},{"key":"2019041607531546400_b53-0700023","article-title":"Phase III trial comparing 3\u20137 days of oritavancin versus 10\u201314 days of vancomycin\/cephalexin in the treatment of patients with skin\/skin structure infections (cSSSI)","volume-title":"Paper presented at 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Giamarellou","year":"2003 ."},{"key":"2019041607531546400_b54-0700023","article-title":"Oritavancin in the treatment of complicated skin and skin structure infections: combined results of two phase 3 multinational trials","volume-title":"Paper presented at 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/46th Annual Infectious Diseases Society of America (IDSA) Meeting","author":"Hartman","year":"2008 ."},{"key":"2019041607531546400_b55-0700023","unstructured":"ClinicalTrials.gov. Oritavancin versus IV vancomycin for the treatment of patients with acute bacterial skin and skin structure infection (SOLO I). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01252719?term=oritavancin&rank=1 (accessed 2011 Aug 27)."},{"key":"2019041607531546400_b56-0700023","unstructured":"ClinicalTrials.gov.  Oritavancin versus IV vancomycin for the treatment of patients with acute bacterial skin and skin structure infection (SOLO II).  http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01252732?term=oritavancin&rank=2 (accessed 2011 Aug 27)."},{"key":"2019041607531546400_b57-0700023","unstructured":"Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment (draft guidance. August 2010). www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071185.pdf (accessed 2011 Aug 31)."},{"key":"2019041607531546400_b58-0700023","unstructured":"Targanta Therapeutics Corporation. Targanta announces launch of oral oritavancin development program against C. difficile bacterial infection. http:\/\/media.integratir.com\/targ\/PressReleases\/TARG%20C%20Diff%20Program%20042108.pdf (accessed 2011 Aug 31)."},{"key":"2019041607531546400_b59-0700023","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.49.5.1695-1700.2005","article-title":"Mixed-lipid storage disorder induced in macrophages and fbroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation","volume":"49","author":"Van Bambeke","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b60-0700023","article-title":"Safety of oritavancin versus vancomycin for treatment of patients with complicated skin and skin structure infections","volume-title":"Paper presented at 19th European Congress of Clinical Microbiology and Infectious Diseases","author":"Moriarty","year":"2009 ."},{"key":"2019041607531546400_b61-0700023","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/0091270009355449","article-title":"Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study","volume":"50","author":"Darpo","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2019041607531546400_b62-0700023","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2146\/ajhp100011","article-title":"Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration","volume":"67","author":"Kumar","year":"2010","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041607531546400_b63-0700023","unstructured":"Targanta Therapeutics Corporation. Briefng document for the anti-infective drugs advisory committee, November 19, 2008. NUVOCID (oritavancin diphosphate for injection) for treatment of complicated skin and skin structure infections. NDA 22-153. www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4394b2-04-Targanta.pdf (accessed 2011 Aug 31)."},{"key":"2019041607531546400_b64-0700023","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041607531546400_b65-0700023","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/1\/23\/28456253\/ajhp0023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T12:02:02Z","timestamp":1555416122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/1\/23\/5112747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110572","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,1,1]]},"published":{"date-parts":[[2013,1,1]]}}}